 Linda Cook
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 16 | 2025 | 205 | 2.770 |
Why?
| | Ovarian Neoplasms | 14 | 2024 | 595 | 2.150 |
Why?
| | Neoplasms, Glandular and Epithelial | 4 | 2016 | 52 | 1.170 |
Why?
| | Biomarkers, Tumor | 9 | 2024 | 1321 | 1.030 |
Why?
| | Contraceptives, Oral, Combined | 2 | 2016 | 18 | 0.900 |
Why?
| | Breast Neoplasms | 10 | 2025 | 2382 | 0.890 |
Why?
| | Triple Negative Breast Neoplasms | 4 | 2019 | 218 | 0.700 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 52 | 0.610 |
Why?
| | Birth Order | 2 | 2016 | 14 | 0.600 |
Why?
| | Alberta | 9 | 2025 | 25 | 0.590 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 143 | 0.560 |
Why?
| | Carcinoma, Endometrioid | 4 | 2024 | 49 | 0.530 |
Why?
| | Immunohistochemistry | 8 | 2024 | 1716 | 0.510 |
Why?
| | Case-Control Studies | 13 | 2025 | 3623 | 0.490 |
Why?
| | Alcohol Drinking | 3 | 2024 | 837 | 0.440 |
Why?
| | Colorectal Neoplasms | 2 | 2022 | 866 | 0.410 |
Why?
| | Risk Factors | 21 | 2025 | 10885 | 0.400 |
Why?
| | Canada | 4 | 2019 | 431 | 0.360 |
Why?
| | Female | 47 | 2025 | 78845 | 0.360 |
Why?
| | Contraception | 1 | 2013 | 170 | 0.340 |
Why?
| | Parity | 4 | 2025 | 111 | 0.340 |
Why?
| | Aged | 24 | 2025 | 26153 | 0.330 |
Why?
| | Cancer Survivors | 4 | 2024 | 337 | 0.320 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 2 | 2020 | 27 | 0.310 |
Why?
| | Middle Aged | 26 | 2025 | 36215 | 0.310 |
Why?
| | Receptors, Progesterone | 4 | 2021 | 243 | 0.280 |
Why?
| | Humans | 49 | 2025 | 145475 | 0.280 |
Why?
| | Bone Neoplasms | 2 | 2025 | 259 | 0.270 |
Why?
| | SEER Program | 2 | 2022 | 229 | 0.270 |
Why?
| | Social Support | 2 | 2023 | 646 | 0.260 |
Why?
| | Contraceptives, Oral | 3 | 2025 | 37 | 0.250 |
Why?
| | Adult | 19 | 2025 | 40777 | 0.250 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2019 | 76 | 0.250 |
Why?
| | Menopause, Premature | 2 | 2024 | 12 | 0.240 |
Why?
| | Receptors, Estrogen | 3 | 2019 | 401 | 0.220 |
Why?
| | Miners | 1 | 2025 | 3 | 0.220 |
Why?
| | Mosaicism | 2 | 2016 | 73 | 0.220 |
Why?
| | Body Mass Index | 4 | 2025 | 2445 | 0.220 |
Why?
| | British Columbia | 4 | 2020 | 24 | 0.220 |
Why?
| | Prospective Studies | 9 | 2024 | 8057 | 0.210 |
Why?
| | PAX2 Transcription Factor | 1 | 2024 | 8 | 0.210 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 102 | 0.200 |
Why?
| | Tissue Array Analysis | 2 | 2020 | 49 | 0.190 |
Why?
| | Point-of-Care Systems | 1 | 2025 | 189 | 0.190 |
Why?
| | Workplace | 1 | 2025 | 272 | 0.180 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2023 | 89 | 0.180 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 99 | 0.180 |
Why?
| | Young Adult | 9 | 2025 | 14219 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2378 | 0.180 |
Why?
| | Dogs | 1 | 2023 | 458 | 0.180 |
Why?
| | Bronchitis, Chronic | 1 | 2022 | 16 | 0.180 |
Why?
| | Sterilization, Tubal | 2 | 2024 | 17 | 0.180 |
Why?
| | Cohort Studies | 6 | 2025 | 6013 | 0.180 |
Why?
| | Cigarette Smoking | 1 | 2023 | 102 | 0.170 |
Why?
| | Horticultural Therapy | 1 | 2021 | 2 | 0.170 |
Why?
| | Neoplasm Grading | 2 | 2020 | 310 | 0.170 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 407 | 0.170 |
Why?
| | Menopause | 3 | 2024 | 326 | 0.170 |
Why?
| | Genome-Wide Association Study | 4 | 2016 | 1407 | 0.170 |
Why?
| | DNA Mismatch Repair | 1 | 2021 | 53 | 0.170 |
Why?
| | Gardening | 1 | 2021 | 13 | 0.170 |
Why?
| | Risk | 3 | 2019 | 919 | 0.170 |
Why?
| | Logistic Models | 3 | 2024 | 2134 | 0.170 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 41 | 0.170 |
Why?
| | Odds Ratio | 5 | 2025 | 1082 | 0.170 |
Why?
| | New Mexico | 2 | 2021 | 99 | 0.160 |
Why?
| | Cyclin E | 1 | 2020 | 23 | 0.160 |
Why?
| | Vegetables | 1 | 2021 | 161 | 0.160 |
Why?
| | Socioeconomic Factors | 2 | 2022 | 1323 | 0.160 |
Why?
| | Washington | 2 | 2020 | 149 | 0.160 |
Why?
| | Pregnancy | 4 | 2020 | 7202 | 0.150 |
Why?
| | Oncogene Proteins | 1 | 2020 | 62 | 0.150 |
Why?
| | Gene Amplification | 1 | 2020 | 118 | 0.150 |
Why?
| | Social Class | 1 | 2022 | 264 | 0.150 |
Why?
| | Rural Population | 1 | 2025 | 659 | 0.150 |
Why?
| | Keratin-7 | 1 | 2019 | 3 | 0.150 |
Why?
| | Matrix Attachment Region Binding Proteins | 1 | 2019 | 6 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 217 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 1443 | 0.140 |
Why?
| | Carcinoma | 1 | 2020 | 225 | 0.140 |
Why?
| | Emotions | 1 | 2023 | 574 | 0.140 |
Why?
| | Lung Diseases | 1 | 2024 | 780 | 0.130 |
Why?
| | Age Factors | 3 | 2025 | 3342 | 0.130 |
Why?
| | Obesity | 3 | 2023 | 3116 | 0.130 |
Why?
| | Ovary | 1 | 2019 | 233 | 0.130 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1327 | 0.130 |
Why?
| | Observer Variation | 3 | 2024 | 357 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 6066 | 0.130 |
Why?
| | Coffee | 1 | 2016 | 15 | 0.120 |
Why?
| | Tea | 1 | 2016 | 17 | 0.120 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 534 | 0.120 |
Why?
| | Beverages | 1 | 2016 | 68 | 0.120 |
Why?
| | Caffeine | 1 | 2016 | 74 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 586 | 0.120 |
Why?
| | Chromosomes, Human, X | 1 | 2016 | 77 | 0.120 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2015 | 7 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3413 | 0.120 |
Why?
| | Glycemic Load | 1 | 2015 | 2 | 0.110 |
Why?
| | Diet | 1 | 2023 | 1277 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 166 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 919 | 0.100 |
Why?
| | Incidence | 2 | 2023 | 2923 | 0.100 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 2121 | 0.100 |
Why?
| | Quality of Life | 2 | 2023 | 3204 | 0.100 |
Why?
| | Registries | 2 | 2020 | 2406 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.100 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 54 | 0.100 |
Why?
| | Interleukin-1alpha | 1 | 2013 | 57 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2016 | 499 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2022 | 1244 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2024 | 1508 | 0.100 |
Why?
| | Breast Feeding | 1 | 2017 | 446 | 0.100 |
Why?
| | Smoking | 3 | 2025 | 1472 | 0.100 |
Why?
| | Exome | 1 | 2014 | 227 | 0.090 |
Why?
| | United States | 4 | 2025 | 16098 | 0.090 |
Why?
| | Population Surveillance | 1 | 2016 | 484 | 0.090 |
Why?
| | Breast | 1 | 2013 | 156 | 0.090 |
Why?
| | Genome, Human | 1 | 2015 | 420 | 0.090 |
Why?
| | Hypertension | 1 | 2021 | 1273 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1101 | 0.090 |
Why?
| | BRCA2 Protein | 2 | 2023 | 68 | 0.090 |
Why?
| | BRCA1 Protein | 2 | 2023 | 82 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1845 | 0.080 |
Why?
| | Postmenopause | 1 | 2013 | 392 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1581 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 317 | 0.080 |
Why?
| | Overweight | 1 | 2016 | 614 | 0.080 |
Why?
| | Transcription Factors | 1 | 2019 | 1734 | 0.080 |
Why?
| | Comorbidity | 1 | 2016 | 1661 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8333 | 0.080 |
Why?
| | NF-kappa B | 1 | 2013 | 666 | 0.080 |
Why?
| | Prevalence | 3 | 2024 | 2865 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1399 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 4075 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2664 | 0.070 |
Why?
| | Vitamin D | 2 | 2025 | 403 | 0.060 |
Why?
| | Premenopause | 2 | 2019 | 125 | 0.060 |
Why?
| | Signal Transduction | 2 | 2024 | 5216 | 0.060 |
Why?
| | Aging | 1 | 2016 | 1969 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2588 | 0.050 |
Why?
| | Menarche | 1 | 2025 | 53 | 0.050 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.050 |
Why?
| | Wnt4 Protein | 1 | 2024 | 20 | 0.050 |
Why?
| | Neurofibromin 1 | 1 | 2023 | 26 | 0.050 |
Why?
| | Animals | 2 | 2023 | 38030 | 0.050 |
Why?
| | Hormone Replacement Therapy | 1 | 2024 | 107 | 0.050 |
Why?
| | Estrogen Replacement Therapy | 1 | 2024 | 143 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2016 | 2158 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 192 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 1374 | 0.050 |
Why?
| | Waist-Hip Ratio | 1 | 2022 | 37 | 0.050 |
Why?
| | Ligands | 1 | 2024 | 665 | 0.040 |
Why?
| | Waist Circumference | 1 | 2022 | 143 | 0.040 |
Why?
| | Smokers | 1 | 2022 | 138 | 0.040 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 37 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2022 | 450 | 0.040 |
Why?
| | ROC Curve | 1 | 2023 | 617 | 0.040 |
Why?
| | Phenotype | 2 | 2021 | 3155 | 0.040 |
Why?
| | Genotype | 2 | 2016 | 1852 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3747 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 241 | 0.040 |
Why?
| | Data Collection | 1 | 2023 | 640 | 0.040 |
Why?
| | Dyspnea | 1 | 2022 | 250 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2020 | 318 | 0.040 |
Why?
| | North America | 1 | 2020 | 302 | 0.040 |
Why?
| | Australia | 1 | 2020 | 288 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2022 | 969 | 0.040 |
Why?
| | United Kingdom | 1 | 2020 | 344 | 0.040 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 28 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 176 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17291 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1767 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2021 | 519 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 503 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2024 | 925 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 688 | 0.030 |
Why?
| | Connecticut | 1 | 2016 | 25 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 46 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2025 | 1097 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 588 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1891 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2017 | 217 | 0.030 |
Why?
| | Women's Health | 1 | 2017 | 314 | 0.030 |
Why?
| | Europe | 1 | 2015 | 418 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1149 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 506 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1997 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 403 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1041 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 847 | 0.020 |
Why?
| | Gene Frequency | 1 | 2014 | 487 | 0.020 |
Why?
| | Male | 4 | 2025 | 72843 | 0.020 |
Why?
| | Mammography | 1 | 2013 | 166 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1082 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 369 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4316 | 0.020 |
Why?
| | DNA Methylation | 1 | 2016 | 674 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2878 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4295 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5905 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2198 | 0.020 |
Why?
| | Lung | 1 | 2022 | 4106 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 972 | 0.020 |
Why?
| | Research Design | 1 | 2015 | 1137 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2067 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1747 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2953 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2906 | 0.010 |
Why?
|
|
Cook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|